ZELLUNA IMMUNOTHERAPY AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

CEO: NJ
Namir Jafar Hassan1978
Chairman of the board: BK
Bent Karsten Jakobsen1959
Years since formation: 8 years; since Mar 1, 2016
Type: Limited company
VAT registered: Yes
Number of employees: 22

Ownership

Number of shares and share classes: 12,119,312; 1 share class
Total number of shareholders: 41; 31 companies, 10 persons

Financials

Total operating income 2023: 7,891,998; NOK
Annual total result 2023: -86,807,393; NOK
Total equity 2023: 123,683,924; NOK

Last update: Oct 14, 2024

Management

Management / administration

Name	Role	Shares
NJ Namir Jafar Hassan 1978	Managing Director/CEO	-

Board

Name	Role	Shares
AT Anders Tuv 1978	Board Member	-
MS Miles Stark Gerson 1980	Board Member	-
HI Hans Ivar Robinson 1967	Board Member	9.7 % indirectly
BK Bent Karsten Jakobsen 1959	Chairman	-
NJ Namir Jafar Hassan 1978	Board Member	-

Others

Name	Role	Shares
P PRICEWATERHOUSECOOPERS AS	Auditor	-
F FORVIS MAZARS OUTSOURCING AS	Accountant	-
A AMESTO ACCOUNTHOUSE AS	Accountant	-

Top 10 individual shareholders

Name	Role	Shares
HI Hans Ivar Robinson 1967	Board Member	9.7 % indirectly
PE Pål Erik Robinson 1969	-	4.36 % indirectly
EH Else Helene Sundt 1979	-	4.22 % indirectly
CS Christian Gruner Sundt 1977	-	3.46 % indirectly
KA Kjetil Myrlid Aasen 1975	-	2.47 % indirectly
HA Hilde Andenæs 1971	-	1.03 % indirectly

Last update: May 25, 2024

Ownership

Company shareholders

Name	Share class	Number of shares	Share
R RADFORSK INVESTERINGSSTIFTELSE	NO0010820731	1,834,205	15.13 %
G Geveran Trading Company Ltd	NO0010820731	1,725,845	14.24 %
I INVEN2 AS	NO0010820731	1,470,466	12.13 %
B BIRK VENTURE AS	NO0010820731	1,175,253	9.7 %
LM Lynch Pierce Fenner Sm Merrill	NO0010820731	1,025,641	8.46 %
SU Switzerland Ag Ubs	NO0010820731	607,427	5.01 %
R RO INVEST AS	NO0010820731	528,196	4.36 %
H HELENE SUNDT AS	NO0010820731	511,113	4.22 %
C CGS HOLDING AS	NO0010820731	419,539	3.46 %
SS Sis Ag Six	NO0010820731	334,944	2.76 %
M MP PENSJON PK	NO0010820731	248,303	2.05 %
M MYRLID AS	NO0010820731	239,701	1.98 %
N NORDA ASA	NO0010820731	230,028	1.9 %
SU Switzerland Ag Ubs	NO0010820731	223,305	1.84 %
K KVANTIA AS	NO0010820731	211,813	1.75 %
S St Catherine's College In The	NO0010820731	159,499	1.32 %
S STAVERN HELSE OG FORVALTNING AS	NO0010820731	125,000	1.03 %
J JANDERSEN KAPITAL AS	NO0010820731	119,850	0.99 %
M MUST INVEST AS	NO0010820731	108,100	0.89 %
J JAKOB HATTELAND HOLDING AS	NO0010820731	95,341	0.79 %
BH Bank Plc Hsbc	NO0010820731	91,384	0.75 %
G GEC HOLDING AS	NO0010820731	83,935	0.69 %
P PRIETA AS	NO0010820731	60,780	0.5 %
T The Bank Of New York Mellon	NO0010820731	60,000	0.5 %
T TRACK AS	NO0010820731	57,020	0.47 %
G GUNNAR KVALHEIM AS	NO0010820731	50,000	0.41 %
J JAHATT AS	NO0010820731	44,953	0.37 %
H H5 VEKST AS	NO0010820731	40,000	0.33 %
N NORLINK INVEST AS	NO0010820731	38,400	0.32 %
T TORSDAG AS	NO0010820731	33,510	0.28 %
G GEØ AS	NO0010820731	30,526	0.25 %
H HMK KAPITAL AS	NO0010820731	25,406	0.21 %
C CAABY AS	NO0010820731	23,535	0.19 %
B BASEN KAPITAL AS	NO0010820731	21,620	0.18 %
TR Tom Rabben 1967	NO0010820731	17,797	0.15 %
B BJELKE HOLDING AS	NO0010820731	15,500	0.13 %
T TRANSVEGA AS	NO0010820731	9,156	0.08 %
T TOWIL AS	NO0010820731	8,936	0.07 %
L LUCELLUM AS	NO0010820731	7,925	0.07 %
B BEWIL AS	NO0010820731	3,360	0.03 %
LW Luise Weigand 1983	NO0010820731	2,000	0.02 %

Last update: May 24, 2024

Financials

in NOK

Summary

Year	2023	2022	2021
Total operating income	7,891,998	13,300,000	13,125,003
Annual Total Result	-86,807,393	-49,071,731	-35,317,250
Total assets	141,677,394	142,808,326	84,104,799
Total liabilities	17,993,470	9,477,822	7,145,630
Total equity	123,683,924	133,330,503	76,959,169

P&L

Year	2023	2022	2021
Total operating income	7,891,998	13,300,000	13,125,003
Total operating costs	101,961,280	65,452,949	47,783,555
Operating result	-94,069,282	-52,152,949	-34,658,552
Financial income/costs	7,261,889	3,081,218	-658,698
Profit before tax	-86,807,393	-49,071,731	-35,317,250
Total tax & extraordinary income/cost	0	0	0
Annual Total Result	-86,807,393	-49,071,731	-35,317,250

Balance overview

Year	2023	2022	2021
Total fixed assets	6,830,420	6,597,350	4,524,021
Total current assets	134,846,974	136,210,976	79,580,778
Total assets	141,677,394	142,808,326	84,104,799
Short term debt	17,993,470	9,477,822	7,145,630
Long term debt	0	0	0
Total liabilities	17,993,470	9,477,822	7,145,630
Contributed capital	123,683,924	133,330,503	76,959,169
Retained earnings	0	0	0
Total equity	123,683,924	133,330,503	76,959,169
Total equity and liabilities	141,677,394	142,808,326	84,104,799

ZELLUNA IMMUNOTHERAPY AS816 823 862